Keywords: Carvedilol; Dronedarone; Pharmacokinetics; Drug interaction; CYP2D6;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Pharmacogenetic; CYP2D6; Genotype; Opioid; Oxycodone; Cancer; Pain; Patient reported outcome; Symptom; Trial design;
Keywords: AUD; Alcohol use disorder; FDA; Food and Drug Administration; MOR; Mu opioid receptor; DOR; Delta opioid receptor; KOR; Kappa opioid receptor; NMDA; N-methyl-d-aspartate; GABA; Gaba amino butyric acid; DSM-IV; Diagnostic and statistical measurement IV; PA
Keywords: Autoimmune hepatitis; Cytochrome P450 2D6; Experimental murine autoimmune hepatitis; Formiminotransferase cyclodeaminase; Soluble liver antigen; Genetic predisposition; Autoantibodies; Ad; adenovirus; AIH; autoimmune hepatitis; CYP2D6; cytochrome P450 2D6
Keywords: 5-HT2A; CYP2D6; DRD2; Genetic polymorphism; Risperidone; Schizophrenia;
Keywords: Pharmacogenetics; Pharmacovigilance; Adverse drug reactions; UGT1A1; TPMT; DPYD; CYP2D6; VKORC1/CYP2C9; CYP2C19; HLA;
Keywords: ACT; artemisinin-based combination therapy; ANOVA; analysis of variance; CI; confidence interval; CYP2D6; cytochrome P450 2D6; DHAP; dihydroartemisinin-piperaquine; G6PD; glucose-6-phosphate dehydrogenase; HR; hazards ratio; IQR; interquartile ratio; MD;
Keywords: CBT; cognitive behavioral therapy; CYP2D6; cytochrome P450 2D6; DHEA; dehydroepiandrosterone; FDA; Food and Drug Administration; GSM; genitourinary syndrome of menopause; MPA; medroxyprogesterone acetate; SERM; selective estrogen receptor modulator; SGB;
Keywords: BC; Breast cancer; CIPN; Chemotherapy-induced peripheral neuropathy; CYP2D6; Cytochrome P450 2D6; CYP3A4; Cytochrome P450 3A4; DN4; Neuropathic pain in 4 questions; DSST; Digit Symbol Substitution Test; EORTC QLQ-C30; European Organisation for Research an
Keywords: CYP2C19; CYP2D6; Depression; GWAS; Pharmacogenetics; Schizophrenia
Keywords: Toremifene; Tamoxifen; Metabolite kinetics; Bioactivation; CYP2D6; CYP3A4; CYP2C9; Pharmacogenomics; PolymorphismsTOR, toremifene; TAM, tamoxifen; SERM, selective estrogen receptor modulator; SSRI, selective serotonin reuptake inhibitor; 4OH, 4-hydroxy; N
Keywords: CYP2D6; Pain management; Hydrocodone; Hydromorphone;
Keywords: Codeine; Pharmacogenetics; Drug interactions; CYP2D6; ABCB1; Post-mortem;
Keywords: Tramadol; Pharmacokinetics; Pharmacodynamics; CYP2D6; ABCB1; OPRM1
Keywords: AIC; Akaike information criteria; BCS; Biopharmaceutics Classification System; BLQ; below the limit of quantification; CI; confidence interval; CYP2D6; cytochrome P450 2D6; GC-MS; gas chromatography coupled to mass spectrometry; IIV; interindividual var
Keywords: anesthesia – genetics; pharmacogenetics; drug–drug interactions; drug–gene interactions; CYP2D6; CYP3A4; CYP2B6; opioid metabolism; OPRM1; OPRK1; UGT2B7; COMT; GABA; ABCB1; MC1R
Celecoxib is a substrate of CYP2D6: Impact on celecoxib metabolism in individuals with CYP2C9*3 variants
Keywords: Celecoxib; CYP2C9; CYP2D6; Drug-drug interaction; Genetic polymorphism; Hydroxy celecoxib;
Predicted activity of UGT2B7, ABCB1, OPRM1, and COMT using full-gene haplotypes and their association with the CYP2D6-inferred metabolizer phenotype
Keywords: UGT2B7; ABCB1; OPRM1; COMT; CYP2D6; Comprehensive pharmacogenetics; Molecular autopsy;
Discovery of DSP-1053, a novel benzylpiperidine derivative with potent serotonin transporter inhibitory activity and partial 5-HT1A receptor agonistic activity
Keywords: Serotonin transporter; 5-HT1A receptor; Antidepressant; Fast onset; Benzylpiperidine; CYP2D6; ZSVLGHSNQJYODD-UHFFFAOYSA-N;
CYP2D6 (C2850T, G1846A, C100T) polymorphisms, haplotypes and MDR analysis in predicting coronary artery disease risk in north-west Indian population: A case-control study
Keywords: μl; microlitre; A; adenine; BMI; body mass index; bp; basepair; C; cytosine; CAD; coronary artery disease; CI; confidence intervals; CNS; central nervous system; CVC; cross validation consistency; CYP2D6; cytochrome P450 2D6; EDTA; ethylenediaminetetra a
Antidepressant polypharmacy and the potential of pharmacokinetic interactions: Doxepin but not mirtazapine causes clinically relevant changes in venlafaxine metabolism
Keywords: Therapeutic drug monitoring; Venlafaxine; Antidepressant polypharmacy; Cytochrome P450; Interaction; CYP2D6; Pharmacokinetics;
Optimization of maintenance therapy of Risperidone with CYP2D6 genetic polymorphisms through an extended translational framework-based prediction of target occupancies/clinical outcomes
Keywords: RO; receptor occupancy; EPS; extrapyramidal symptoms; PK; pharmacokinetic; PD; pharmacodynamic; EM; extensive metabolizer; IM; intermediate metabolizer; PM; poor metabolizer; PBPKPD; physiology-based pharmacokinetic and pharmacodynamic; P-gp; P-glycoprote
Effect of genetic polymorphism on the inhibition of dopamine formation from p-tyramine catalyzed by brain cytochrome P450 2D6
Keywords: CYP2D6; Dopamine formation; Genetic polymorphism; Drug interaction; CLint; intrinsic clearance; CYP or P450; cytochrome P450; DHEA; dehydroepiandrosterone; IC50; 50% inhibitory concentration; Iu; unbound concentration of the inhibitor; Ki; inhibitory cons
CYP2D6 pharmacogenomics
Keywords: cyp2d6; Pharmacogenomics; Genomic drug label; Clinical pharmacogenomics; CYP2D6 substrates; Structure of CYP2D6;
CYP2C9, CYPC19 and CYP2D6 gene profiles and gene susceptibility to drug response and toxicity in Turkish population
Keywords: Genetic polymorphism; Turkish population; CYP2C9; CYP2C19; CYP2D6; Cytochrome P450;
Effect of 22 CYP2D6 variants found in the Chinese population on tolterodine metabolism in vitro
Keywords: CYP2D6; Allelic variants; Tolterodine; Drug metabolism; In vitro;
Increased DNA Methylation of ABCB1, CYP2D6, and OPRM1 Genes in Newborn Infants of Methadone-Maintained Opioid-Dependent Mothers
Keywords: In-utero methadone; DNA methylation; newborn infants; ABCB1; CYP2D6; OPRM1; CpG; Cytosine-phosphate-guanine dinucleotide; DEPCAT; Deprivation score; MMOD; Methadone-maintained opioid-dependent; NAS; Neonatal abstinence syndrome;
Pharmacogenetics of antidepressant drugs: State of the art and clinical implementation - recommendations from the French National Network of Pharmacogenetics
Keywords: Pharmacogenetics; Antidepressant drugs; Psychiatry; CYP2C19; CYP2D6;
Pharmacogénétique des médicaments antidépresseurs : état des connaissances et des pratiques - recommandations du Réseau national de pharmacogénétique (RNPGx)
Keywords: Pharmacogénétique; Antidépresseurs; Psychiatrie; CYP2C19; CYP2D6;
CYP2D6 and CYP2A6 biotransform dietary tyrosol into hydroxytyrosol
Keywords: Hydroxytyrosol (PubChem CID: 82755); Tyrosol (PubChem CID: 10393); Nicotine (PubChem CID: 942); Coumarin (PubChem CID: 323); Dextromethorphan (PubChem CID: 6916184); Tryptamine (PubChem CID: 1150); Methoxsalen (PubChem CID: 4114); Tranylcypromine (PubChem
Intuitive pharmacogenetic dosing of risperidone according to CYP2D6 phenotype extrapolated from genotype in a cohort of first episode psychosis patients
Keywords: Pharmacogenetics; Pharmacokinetics; Antipsychotic; CYP2D6;
In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation
Keywords: Drug-drug interactions; CYP2D6; Bupropion; Enzyme regulation; In vitro to in vivo extrapolation; AUC; area under plasma concentration time curve; CYP; cytochrome P450; DDI; drug-drug interaction; fm; fraction metabolized; IVIVE; in vitro to in vivo extrap
Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: An overview about well-established and recently emerging clinical data
Keywords: ABCC1/MRP; ATP binding cassette subfamily C member 1/ multidrug resistance protein; ABVD; doxorubicine-bleomycin-vinblastine-dacarbazine; AC; doxorubicin-cyclophosphamide; ANC; absolute neutrophil count; ASCO; American Society of Clinical Oncology; AUC; a
Pharmacogenetics in obstetric anesthesia
Keywords: labor; cesarean delivery; pain; analgesia; opioids; ephedrine; genetics; pharmacogenetics; polymorphisms; OPRM1; ADRB2; CYP2D6;
Application of a physiologically based pharmacokinetic model for the evaluation of single-point plasma phenotyping method of CYP2D6
Keywords: CYP2D6; Phenotyping method; Physiologically based pharmacokinetic model; Virtual population;
Apport de la pharmacogénétique à la pharmacovigilance
Keywords: Pharmacogénétique; Pharmacovigilance; Effets indésirables médicamenteux; UGT1A1; TPMT; DPYD; CYP2D6; VKORC1/CYP2C9; CYP2C19; HLA;
Sequencing CYP2D6 for the detection of poor-metabolizers in post-mortem blood samples with tramadol
Keywords: Pharmacogenetics; CYP2D6; Poor metabolizers; Tramadol; Post-mortem; Forensic toxicology;
Detection of CYP2D6 polymorphism using Luminex xTAG technology in autism spectrum disorder: CYP2D6 activity score and its association with risperidone levels
Keywords: CYP2D6; Luminex; Activity score; Risperidone; Autism spectrum disorder; CYP2D6; Cytochrome P450 2D6; PM; poor metabolizer; IM; intermediate metabolizer; EM; extensive metabolizer; UM; ultra-rapid metabolizer; ASD; autism spectrum disorder; F; function; DF
Effects of Hypericum perforatum extract and its main bioactive compounds on the cytotoxicity and expression of CYP1A2 and CYP2D6 in hepatic cells
Keywords: Hypericum perforatum; Hypericin; Hyperforin; CYP1A2; CYP2D6; Hepatic cells; Herb-drug interactions
Non-alcoholic fatty liver disease (NAFLD) potentiates autoimmune hepatitis in the CYP2D6 mouse model
Keywords: Autoimmune hepatitis; NAFLD; CYP2D6; Mouse model; Hepatic fibrosisNAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; HCC, hepatocellular carcinoma; AIH, autoimmune hepatitis; CYP2D6, cytochrome P450 2D6; LKM-1, type 1 liver/kid
Pharmacogenomics in Psychiatric Practice
Keywords: Psychiatric pharmacogenomics; Pharmacogenomic testing; Antidepressants; Antipsychotics; 2D6; CYP2D6; SLC6A4; OPRM1;
Clinical Utility and Economic Impact of CYP2D6 Genotyping
Keywords: CYP2D6; CYP2D6 genotyping; Pharmacogenetics; Pharmacoeconomics;
Lotus leaf alkaloid fraction can strongly inhibit CYP2D6 isoenzyme activity
Keywords: Lotus; Nelumbo nucifera; Alkaloid; CYP2D6; Drug interaction;
The role of PON1 and CYP2D6 genes in susceptibility to organophosphorus chronic intoxication in Egyptian patients
Keywords: PON-1; CYP2D6; Organophosphates; Chronic intoxication;
Pharmacogenetics of CYP2D6 and tamoxifen therapy: Light at the end of the tunnel?
Keywords: Pharmacogenetics; Breast cancer; CYP2D6; Tamoxifen; Polymorphisms;
Increased prevalence of functional minor allele variants of drug metabolizing CYP2B6 and CYP2D6 genes in Roma population samples
Keywords: CYP2B6; CYP2D6; Pharmacogenetics; Roma; Hungarian
Metabolism of palmatine by human hepatocytes and recombinant cytochromes P450
Keywords: Palmatine; Mass spectrometry; Metabolism; Cytochrome P450; CYP2D6;
Effects of cytochrome P450 2D6 and 3A5 genotypes and possible coadministered medicines on the metabolic clearance of antidepressant mirtazapine in Japanese patients
Keywords: CYP2D6; CY3A5; Genetic polymorphisms; Mirtazapine; Plasma concentration
Benzydamine N-oxygenation as an index for flavin-containing monooxygenase activity and benzydamine N-demethylation by cytochrome P450 enzymes in liver microsomes from rats, dogs, monkeys, and humans
Keywords: FMO3; FMO1; CYP2D6; NADPH; Preheating of liver microsomesFMO, flavin-containing monooxygenase (FMO, EC 1.14.13.8); P450, general term for cytochrome P450 (EC 1.14.14.1); CYP, individual form of P450
Serum flecainide S/R ratio reflects the CYP2D6 genotype and changes in CYP2D6 activity
Keywords: Flecainide; S/R ratio; CYP2D6; Genotype; CYP2D6 inhibitor